Cancer Stem Cells and Tumor Microenvironment

Guest Editor:

**Dr. Vita Golubovskaya**
Promab Biotechnologies, Director, Richmond, CA, USA; Adjunct Associate Research Professor, Department of Radiation Oncology, University at Buffalo-SUNY, Buffalo, NY, USA
vitagol@yahoo.com

Deadline for manuscript submissions:  
**closed (15 November 2015)**

**Message from the Guest Editor**

Dear Colleagues

Cancer stem cells or tumor initiating cells overexpress specific intra- and extra-cellular markers that result in their tumorigenic and high metastatic activity. In addition, the unique intracellular signaling and metabolism of cancer stem cells drive aggressive behavior of these cells. Cancer stem cells cross talk with microenvironment components: immune cells, blood vessels, fibroblasts, extracellular matrix proteins), which is important to understand for future development of anti-cancer therapeutics. The genomics, proteomics, and metabolomics technology should be applied to the characterization of these cells and microenvironment to develop personalized medicine approaches.

Dr. Vita Golubovskaya
*Guest Editor*

mdpi.com/si/4995
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 18 days after submission; acceptance to publication is undertaken in 4.14 days (median values for papers published in the first six months of 2018).

Contact us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI